Cellontech Registers Prescription Code for Catizol at Gangbuk Samsung Hospital

[Asia Economy Reporter Hyungsoo Park] Cellontech, a subsidiary of SC Engineering, has significantly expanded the sales channels for 'Cartizol,' the first collagen intra-articular injection developed in Korea.

On the 26th, SC Engineering announced that the collagen-based tissue supplement 'Cartizol' has registered prescription codes at 21 locations, including tertiary general hospitals and semi-general hospitals specializing in joints. SC Engineering holds a 51% stake in Cellontech.

The additional tertiary general hospitals that successfully landed include ▲Kangbuk Samsung Hospital ▲Soonchunhyang University Seoul Hospital ▲Chung-Ang University Hospital ▲Hanyang University Hospital ▲Kyungpook National University Hospital ▲Keimyung University Dongsan Medical Center ▲Daegu Catholic University Hospital. Semi-general hospitals with multiple branch hospitals include ▲Himchan Hospital ▲Nanuri Hospital ▲Bareun Sesang Hospital.

A company official stated, "Landing not only in tertiary general hospitals but also in semi-general hospitals, which are specialized in joint diseases and have a high concentration of patient demand, is significant in terms of trust, recognition, and scale." He added, "With the full-scale prescription at tertiary general and semi-general hospitals, we will make every effort to strengthen the nationwide distribution network and expand prescriptions centered on clinics to link this to increased sales of Cartizol."

Cartizol is an intra-articular injection that administers bio-collagen into the joint cavity to supplement defective or damaged articular cartilage. Its technology has been verified through certification as a New Health Technology (NET) by the Ministry of Health and Welfare and recognition as a new medical technology.

This content was produced with the assistance of AI translation services.